Although the relative contribution of each of these actions to the preservation of vascular function cannot be directly extrapolated from the current findings, the results of this study provide a rationale for the therapeutic use of unacylated ghrelin in the treatment of vascular dysfunction and cardiovascular disease in conditions associated with altered peptide levels, such as obesity and insulin resistance. The gene discussed is GHRL; the disease is Insulin resistance.